Use of semaphorin-4D inhibitory molecules with an immune modulating therapy to inhibit tumor growth and metastases
Provided herein are methods for inhibiting, delaying, or reducing tumor growth and metastases of Plexin-B1-expressing cancer cells in a subject, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) in combination with an effective amount of at least one other immune modulating therapy.
1. A method for inhibiting, delaying, or reducing solid tumor growth in a subject with cancer, comprising
(a) determining the levels of B cells and/or T cells in a subject with cancer; and
(b) administering to the subject an effective amount of an isolated antibody or antigen-binding fragment thereof that specifically binds to semaphorin-4D (SEMA4D) if the levels of B cells and/or T cells per microliter of blood in the subject are at least 1.5 times the mean number of B cells and/or T cells in circulation in other cancer patients with solid tumors, thereby treating the subject with cancer,
wherein the antibody or antigen-binding fragment thereof that specifically binds to SEMA4D comprises a variable heavy chain (VH) comprising VHCDRs 1-3 comprising SEQ ID NOs 6, 7, and 8, respectively, and a variable light chain (VL) comprising VLCDRs 1-3 comprising SEQ ID NOs 14, 15, and 16, respectively.
2. The method of claim 1 , wherein the levels of B cells, and/or T cells are measured as a percentage of total blood cells or as the mean number per microliter of blood.
3. The method of claim 1 , wherein the T cells are CD8+ T cells.
4. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof that specifically binds to SEMA4D inhibits SEMA4D interaction with its receptor.
5. The method of claim 4 , wherein the receptor is Plexin-B1, Plexin-B2, CD72, or a combination thereof.
6. The method of claim 5 , wherein the antibody or antigen-binding fragment thereof that specifically binds to SEMA4D inhibits SEMA4D-mediated Plexin-B1 signal transduction.
7. The method of claim 1 , wherein the VH and VL comprise, respectively, SEQ ID NO: 9 and SEQ ID NO: 17 or SEQ ID NO: 10 and SEQ ID NO: 18.
8. The method of claim 1 , further comprising administering to the subject an effective amount of at least one other immune modulating therapy if the levels of B cells, and/or T cells per microliter of blood in the subject is at least 1.5 times the mean number of B cells and/or T cells in circulation in other cancer patients with solid tumors,
wherein the at least one other immune modulating therapy comprises adoptive T cell therapy, an immune checkpoint blockade inhibitor selected from an anti-Programmed Cell Death 1 (PD-1) antibody, an anti-Programmed Death-Ligand 1 (PD-L1) antibody, an anti-Lymphocyte Activation Gene 3 (LAG3) antibody, an anti-B7-H3 antibody, an antigen-binding fragment thereof, or a combination thereof, a regulatory T cell (Treg) modulator comprising cyclophosphamide, or a combination thereof.
9. The method of claim 8 , wherein the antibody or antigen-binding fragment thereof that specifically binds to SEMA4D and the at least one immune modulating therapy are administered separately or concurrently.
10. The method of claim 8 , wherein the adoptive T cell therapy comprises tumor-infiltrating lymphocytes (TIL) recovered from resected patient tumor, T cells transduced with a chimeric antigen receptor, or a combination thereof.
11. The method of claim 10 , wherein the recovered TIL have been expanded in vitro.
12. The method of claim 11 , wherein the in vitro expansion comprises incubating the recovered TIL with allo-reactive feeder cells, interleukin-2 (IL-2), anti-CD3 antibody, or any combination thereof.
13. The method of claim 12 , wherein the in vitro expansion enriches for cytotoxic CD8+ T cells.
14. The method of claim 8 , wherein administration of the combination of the antibody or antigen-binding fragment thereof that specifically binds to SEMA4D and the at least one immune modulating therapy results in enhanced therapeutic efficacy relative to administration of either agent alone.
15. The method of claim 2 , wherein the levels of B cells and/or T cells per microliter of blood in the subject are about 1.5 to about 5 times the mean number of B cells and/or T cells in circulation in other cancer patients.
16. The method of claim 15 , wherein the levels of B cells and/or T cells per microliter of blood in the subject range from about 147 to about 588 and from about 1173 to about 3910, respectively.
17. The method of claim 2 , wherein the levels of B cells and/or T cells per microliter of blood in the subject fall within or above the range of B cells and/or T cells of healthy, non-cancer patients.
18. The method of claim 15 , wherein the levels of B cells and/or T cells per microliter of blood in the subject range from about 225 to about 275 or more and from about 1350 to about 1650 and more, respectively.
19. The method of claim 1 , wherein the cancer is carcinoma, lymphoma, blastoma, sarcoma, squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastrointestinal cancer, gastric cancer, pancreatic cancer, neuroendocrine cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, brain cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, esophageal cancer, salivary gland carcinoma, kidney cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, head and neck cancer, or a combination thereof.
20. The method of claim 1 , wherein the subject is human.